Is Mirum Pharmaceuticals About to Soar in 2026?

Mirum Pharmaceuticals achieved positive operating cash flow in 2025 and reported strong product momentum with Livmarli net product sales rising 69% year-over-year to $359 million and combined bile-acid therapy sales (Cholbam and Ctexli) up 31% to $161 million; company 2026 revenue guidance is $630–$650 million. Regulatory and pipeline progress includes 2025 FDA approvals for Ctexli (CTX) and a Livmarli tablet (ALGS, PFIC), the Jan. 26, 2026 acquisition of Bluejay Therapeutics adding brelovitug for HDV, imminent Phase 2B volixibat PSC results in Q2 2026 with potential accelerated approval in H2 2026, Phase 3 brelovitug readout in H2 2026, and accelerated Livmarli Phase 3 enrollment/ topline readout by end-2026 — a set of near-term catalysts that could materially influence the stock after a >2x share-price gain over the prior 12 months.

Analysis

Market structure: Mirum (MIRM) is the clear near-term winner — Livmarli drove net product sales to $359M (up 69% y/y) and management guides $630–650M for 2026, implying >55% of revenue currently depends on Livmarli and bile-acid franchise. If volixibat (PSC) and brelovitug (HDV) succeed, Mirum gains pricing power in orphan hepatology with limited direct competitors (no approved PSC/HDV U.S. therapies), tightening demand vs. constrained supply of approved orphan drugs and pressuring payors on cost. Cross-asset effects: positive readouts should compress Mirum equity implied volatility and tighten small-cap biotech credit spreads; minimal direct FX/commodity impact but sector flows could lift XBI and narrow CDS on high-quality small biotechs.

Risk assessment: Tail risks are binary clinical/regulatory failures (Phase 2B volixibat or Phase 3 brelovitug negative) or FDA denial of accelerated approval — each could plausibly cut MIRM >50% within days. Time buckets: immediate (days) = IV and price swings around Q2 readout; short-term (weeks–months) = H2 2026 topline data and enrollment milestones; long-term (12–24 months) = commercial rollout, reimbursement and potential dilution for Phase 3 programs. Hidden dependencies include payer access for ultra-rare indications, integration risk from the Jan 26, 2026 Bluejay acquisition, and concentration risk from Livmarli representing >50% of near-term revenues.

Trade implications: Direct play — establish a 2–3% portfolio long in MIRM ahead of the Q2 2026 volixibat readout, size to risk (stop-loss −30%). Hedge market beta by shorting XBI (50–75% notional vs. MIRM) to isolate idiosyncratic risk. Options: buy a defined-risk call spread expiring Sept/Oct 2026 to capture H2 catalysts (max loss = premium) and buy Jan 2028 LEAP calls (1% notional) financed by selling nearer-term calls to monetize IV; avoid naked longs around data. Sector rotation: overweight commercial-stage rare-disease biotech, underweight discovery-only small caps until clarity on reimbursement.

Contrarian angles: The market is likely underpricing commercialization and reimbursement risk — consensus treats multiple late-stage readouts as additive to valuation without stress-testing payer pushback. Historical parallel: Intercept’s regulatory/backlash episode shows approval does not guarantee durable pricing or uptake; Mirum’s concentration in Livmarli amplifies that vulnerability. Watch for mispricings: if implied move <30% into binary events or shares run up >50% pre-data, consider trimming to lock gains; conversely, a clean negative readout that cuts price >40% may create a high-conviction deep-value entry if fundamentals (cash flow positive, >$600M guidance) remain intact.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in MIRM within 4–8 weeks before the Q2 2026 volixibat readout; use a hard stop-loss at −30% and plan to add up to +1–2% on a positive topline that clears primary endpoints.
• Hedge idiosyncratic risk by shorting XBI equal to 50–75% of the MIRM notional exposure (dollar-neutral setup) to isolate Mirum-specific catalysts while limiting sector beta.
• Implement defined-risk options around binary events: buy a Sept/Oct 2026 MIRM call spread sized to 0.5–1% portfolio risk for the H2 catalyst window; buy Jan 2028 LEAP calls (1% notional) financed by selling near-term calls to capture long-term upside while collecting premium.
• Reduce/avoid exposure to discovery-stage small-cap biotech names and reallocate to commercial-stage rare-disease biotechs; if MIRM shares rally >50% pre-readout, trim core position by 25–50% to crystallize gains.
• Set explicit triggers to act: if volixibat or brelovitug readouts are positive and management signals favorable FDA interactions, increase MIRM exposure by +2% within 2 weeks; if either readout is negative and stock falls >40%, reassess for a potential 1–2% opportunistic buy only after confirming cash runway and no adverse regulatory rulings.